Documents et medias


Toutes les vidéos


Tumor Assessment Using RECIST 1.1 Criteria and Alternative Criteria for Immuno-oncology Trials

Toutes les brochures

White papers

Understanding Novel Response Patterns of Immunotherapies

Immunotherapies display novel response patterns that affect the design of imaging based studies and the subsequent evaluation of imaging data. Applying traditional chemotherapy-based response assumptions to immunotherapy trials can result in inaccurate interpretation of response, premature therapy termination, and unnecessary removal of subjects from a trial. Our unique solutions for medical image analysis and management and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy.

Tous les white papers

Case studies

How automation can improve data consistency/value, and streamline study workflow

Toutes les études de cas

Publications scientifiques

iBiopsy® Lung Cancer Screening: a unique AI powered end to end CADe CADx SaMD for early diagnosis

Yan Liu [1], Benoit Huet [1] – Affiliations: [1] Median Technologies, 1800 Route des Crêtes, 06560 Valbonne, France.

Présenté le 28 Nov. 2021 au RSNA AI Theater – Réunion annuelle du RSNA, 28 Nov. –  2 Déc. 2021, à Chicago, IL, USA. Cette présentation apporte une vision de la performance d’iBiopsy® Lung Cancer Screening CADx portant spécifiquement sur la caractérisation du cancer pulmonaire de stade 1.

Toutes les publications scientifiques